288 related articles for article (PubMed ID: 30089730)
1. FOXM1 contributes to treatment failure in acute myeloid leukemia.
Khan I; Halasi M; Patel A; Schultz R; Kalakota N; Chen YH; Aardsma N; Liu L; Crispino JD; Mahmud N; Frankfurt O; Gartel AL
JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089730
[TBL] [Abstract][Full Text] [Related]
2. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
[TBL] [Abstract][Full Text] [Related]
3. Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species.
Garcia JS; Huang M; Medeiros BC; Mitchell BS
Clin Cancer Res; 2016 Apr; 22(8):1978-88. PubMed ID: 26634271
[TBL] [Abstract][Full Text] [Related]
4. Favorable outcomes of NPM1
Khan I; Kaempf A; Raghuwanshi S; Chesnokov M; Zhang X; Wang Z; Domling A; Tyner JW; Camacho C; Gartel AL
Blood Cancer J; 2023 Aug; 13(1):128. PubMed ID: 37607920
[No Abstract] [Full Text] [Related]
5. Over-expression of FoxM1 is associated with adverse prognosis and FLT3-ITD in acute myeloid leukemia.
Liu LL; Zhang DH; Mao X; Zhang XH; Zhang B
Biochem Biophys Res Commun; 2014 Mar; 446(1):280-5. PubMed ID: 24582753
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of FoxM1 transcription factor contributes to curcumin-induced inhibition of survival, angiogenesis, and chemosensitivity in acute myeloid leukemia cells.
Zhang JR; Lu F; Lu T; Dong WH; Li P; Liu N; Ma DX; Ji CY
J Mol Med (Berl); 2014 Dec; 92(12):1319-30. PubMed ID: 25179295
[TBL] [Abstract][Full Text] [Related]
7. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-149 Increases the Sensitivity of Colorectal Cancer Cells to 5-Fluorouracil by Targeting Forkhead Box Transcription Factor FOXM1.
Liu X; Xie T; Mao X; Xue L; Chu X; Chen L
Cell Physiol Biochem; 2016; 39(2):617-29. PubMed ID: 27415661
[TBL] [Abstract][Full Text] [Related]
9. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
Roeten MSF; van Meerloo J; Kwidama ZJ; Ter Huizen G; Segerink WH; Zweegman S; Kaspers GJL; Jansen G; Cloos J
Cells; 2021 Mar; 10(3):. PubMed ID: 33802801
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo.
Schnerch D; Schüler J; Follo M; Felthaus J; Wider D; Klingner K; Greil C; Duyster J; Engelhardt M; Wäsch R
Oncotarget; 2017 Mar; 8(13):21153-21166. PubMed ID: 28416751
[TBL] [Abstract][Full Text] [Related]
11. FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML.
Sheng Y; Yu C; Liu Y; Hu C; Ma R; Lu X; Ji P; Chen J; Mizukawa B; Huang Y; Licht JD; Qian Z
Nat Commun; 2020 Feb; 11(1):928. PubMed ID: 32066721
[TBL] [Abstract][Full Text] [Related]
12. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2.
Karathedath S; Rajamani BM; Musheer Aalam SM; Abraham A; Varatharajan S; Krishnamurthy P; Mathews V; Velayudhan SR; Balasubramanian P
PLoS One; 2017; 12(5):e0177227. PubMed ID: 28505160
[TBL] [Abstract][Full Text] [Related]
13. Nuclear FOXM1 drives chemoresistance in AML.
Khan I; Halasi M; Zia MF; Gann P; Gaitonde S; Mahmud N; Gartel AL
Leukemia; 2017 Jan; 31(1):251-255. PubMed ID: 27694928
[No Abstract] [Full Text] [Related]
14. The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia.
Nakamura S; Hirano I; Okinaka K; Takemura T; Yokota D; Ono T; Shigeno K; Shibata K; Fujisawa S; Ohnishi K
Carcinogenesis; 2010 Nov; 31(11):2012-21. PubMed ID: 20823107
[TBL] [Abstract][Full Text] [Related]
15. Cadmium chloride enhances cisplatin sensitivity in osteosarcoma cells by reducing FOXM1 expression.
Hu K; Xie W; Ni S; Yan S; Tian G; Qi W; Duan Y
Oncol Rep; 2020 Aug; 44(2):650-660. PubMed ID: 32627005
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
[TBL] [Abstract][Full Text] [Related]
17. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.
Handschuh L; Kaźmierczak M; Milewski MC; Góralski M; Łuczak M; Wojtaszewska M; Uszczyńska-Ratajczak B; Lewandowski K; Komarnicki M; Figlerowicz M
Int J Oncol; 2018 Mar; 52(3):656-678. PubMed ID: 29286103
[TBL] [Abstract][Full Text] [Related]
19. Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.
Cremer A; Ellegast JM; Alexe G; Frank ES; Ross L; Chu SH; Pikman Y; Robichaud A; Goodale A; Häupl B; Mohr S; Rao AV; Walker AR; Blachly JS; Piccioni F; Armstrong SA; Byrd JC; Oellerich T; Stegmaier K
Cancer Discov; 2020 Feb; 10(2):214-231. PubMed ID: 31771968
[TBL] [Abstract][Full Text] [Related]
20. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B
Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]